Don Sapatkin

Articles by Don Sapatkin

Gene therapies are incredibly expensive and tend to benefit small numbers of people, a combination that presents myriad financing challenges for patients, providers, payers and producers. A new study explored some of the options.

Between 9% and 12% of American adults have insomnia, and 85% of them also are diagnosed with comorbid conditions like type 2 diabetes and dementia. While the numerous health consequences of comorbid insomnia have been well-documented, the additional costs for specific disease groups have not been measured in large studies — until now.

Researchers have spent a century trying to develop a vaccine against malaria, one of the world’s biggest killers. The first shot to be approved, two years ago, is 30% effective. A new one, in the works for three decades, has a reported 77% efficacy and a licensee with the capacity to produce 200 million doses a year.